RVTY
REVVITY, INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$143.45
−2.24%Next report
Analyst consensus
- Next report date
- Oct 26, 2026
- EPS estimate
- $1.28
- Revenue estimate
- $694.4M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $1.41
- EPS estimate
- $1.21
- Revenue actual
- $711.0M
- Revenue estimate
- $703.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.1%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $142
- PT range
- $126 – $165
- Analysts
- 3
2 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $1.21 | $1.41 | Beat 16.53% | $711.0M |
| May 5, 2026 | $1.02 | $1.06 | Beat 3.92% | $711.1M |
| Feb 2, 2026 | $1.63 | $1.70 | Beat 4.29% | $772.1M |
| Jan 31, 2025 | $1.37 | $1.42 | Beat 3.65% | $729.4M |
| Feb 1, 2024 | $1.15 | $1.25 | Beat 8.70% | $695.9M |
| Aug 1, 2023 | $1.18 | $1.21 | Beat 2.54% | $709.1M |
| May 11, 2023 | $1.06 | $1.01 | Miss -4.72% | $674.9M |
| Feb 14, 2023 | $1.66 | $1.70 | Beat 2.41% | $741.2M |
| Oct 1, 2022 | $1.44 | $0.55 | Miss -61.87% | $711.8M |
| Jul 2, 2022 | $2.01 | $1.42 | Miss -29.35% | $1.2B |
| Mar 31, 2022 | $2.12 | $1.40 | Miss -33.96% | $1.3B |
| Dec 31, 2021 | — | $1.50 | — | $1.4B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 26, 2026